AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-91
Results: 1-25/91
LONG-TERM RESULTS AFTER INFERIOR VENA-CAVAL RESECTION DURING RETROPERITONEAL LYMPHADENECTOMY FOR METASTATIC GERM-CELL CANCER
Authors: BECK SDW LALKA SG DONOHUE JP
Citation: Sdw. Beck et al., LONG-TERM RESULTS AFTER INFERIOR VENA-CAVAL RESECTION DURING RETROPERITONEAL LYMPHADENECTOMY FOR METASTATIC GERM-CELL CANCER, Journal of vascular surgery, 28(5), 1998, pp. 808-814
IDENTIFICATION OF CLINICAL STAGE A NONSEMINOMATOUS TESTIS CANCER-PATIENTS AT EXTREMELY LOW-RISK FOR METASTATIC DISEASE - A COMBINED APPROACH USING QUANTITATIVE IMMUNOHISTOCHEMICAL, HISTOPATHOLOGIC, AND RADIOLOGIC ASSESSMENT
Authors: LEIBOVITCH I FOSTER RS KOPECKY KK ALBERS P ULBRIGHT TM DONOHUE JP
Citation: I. Leibovitch et al., IDENTIFICATION OF CLINICAL STAGE A NONSEMINOMATOUS TESTIS CANCER-PATIENTS AT EXTREMELY LOW-RISK FOR METASTATIC DISEASE - A COMBINED APPROACH USING QUANTITATIVE IMMUNOHISTOCHEMICAL, HISTOPATHOLOGIC, AND RADIOLOGIC ASSESSMENT, Journal of clinical oncology, 16(1), 1998, pp. 261-268
RETROPERITONEAL LYMPHADENECTOMY IN STAGING AND TREATMENT - THE DEVELOPMENT OF NERVE-SPARING TECHNIQUES
Authors: DONOHUE JP FOSTER RS
Citation: Jp. Donohue et Rs. Foster, RETROPERITONEAL LYMPHADENECTOMY IN STAGING AND TREATMENT - THE DEVELOPMENT OF NERVE-SPARING TECHNIQUES, Urologic clinics of North America, 25(3), 1998, pp. 461
CAN RETROPERITONEAL LYMPHADENECTOMY BE OMITTED IN SOME PATIENTS AFTERCHEMOTHERAPY
Authors: FOSTER RS DONOHUE JP
Citation: Rs. Foster et Jp. Donohue, CAN RETROPERITONEAL LYMPHADENECTOMY BE OMITTED IN SOME PATIENTS AFTERCHEMOTHERAPY, Urologic clinics of North America, 25(3), 1998, pp. 479
ADVANCED TESTICULAR CANCER - UPDATE FOR UROLOGISTS
Authors: EINHORN LH DONOHUE JP
Citation: Lh. Einhorn et Jp. Donohue, ADVANCED TESTICULAR CANCER - UPDATE FOR UROLOGISTS, The Journal of urology, 160(6), 1998, pp. 1964-1969
IS RETROPERITONEAL LYMPH-NODE DISSECTION NECESSARY FOR ADULT PARATESTICULAR RHABDOMYOSARCOMA
Authors: HERMANS BP FOSTER RS BIHRLE R LITTLE S SANDLER A EINHORN LH DONOHUE JP
Citation: Bp. Hermans et al., IS RETROPERITONEAL LYMPH-NODE DISSECTION NECESSARY FOR ADULT PARATESTICULAR RHABDOMYOSARCOMA, The Journal of urology, 160(6), 1998, pp. 2074-2077
COMBINED POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION AND RESECTION OF CHEST TUMOR UNDER THE SAME ANESTHETIC IS APPROPRIATE BASEDON MORBIDITY AND TUMOR PATHOLOGY
Authors: TOGNINI PG FOSTER RS MCGRAW P HEILMAN D BIHRLE R ROWLAND RG WAHLE GR EINHORN LH DONOHUE JP
Citation: Pg. Tognini et al., COMBINED POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION AND RESECTION OF CHEST TUMOR UNDER THE SAME ANESTHETIC IS APPROPRIATE BASEDON MORBIDITY AND TUMOR PATHOLOGY, The Journal of urology, 159(6), 1998, pp. 1833-1835
FERTILITY UPDATE ON NERVE SPARING RPLND IN CLINICAL STAGE-I NONSEMINOMA
Authors: FOSTER RS RAGAN DC BIHRLE R WAHLE GR HERMANS BP DONOHUE JP
Citation: Rs. Foster et al., FERTILITY UPDATE ON NERVE SPARING RPLND IN CLINICAL STAGE-I NONSEMINOMA, The Journal of urology, 159(5), 1998, pp. 174-174
RECURRENCES IN NONSEMINOMATOUS GERM-CELL TUMORS AFTER POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION (PCRPLND)
Authors: RAGAN DC FOSTER RS NICHOLS CR DONOHUE JP
Citation: Dc. Ragan et al., RECURRENCES IN NONSEMINOMATOUS GERM-CELL TUMORS AFTER POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION (PCRPLND), The Journal of urology, 159(5), 1998, pp. 175-175
RISK OF METASTASES IN CLINICAL STAGE-I NONSEMINOMA MANAGED BY RPLND
Authors: HERMANS BP SWEENEY CJ EINHORN LII FOSTER RS DONOHUE JP
Citation: Bp. Hermans et al., RISK OF METASTASES IN CLINICAL STAGE-I NONSEMINOMA MANAGED BY RPLND, The Journal of urology, 159(5), 1998, pp. 176-176
EN-BLOC NEPHRECTOMY IN PATIENTS UNDERGOING POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION FOR NONSEMINOMATOUS TESTIS CANCER - INDICATIONS, IMPLICATIONS AND OUTCOMES
Authors: NASH PA LEIBOVITCH I FOSTER RS BIHRLE R ROWLAND RG DONOHUE JP
Citation: Pa. Nash et al., EN-BLOC NEPHRECTOMY IN PATIENTS UNDERGOING POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION FOR NONSEMINOMATOUS TESTIS CANCER - INDICATIONS, IMPLICATIONS AND OUTCOMES, The Journal of urology, 159(3), 1998, pp. 707-710
BILATERAL TESTICULAR-TUMORS - MANAGEMENT AND OUTCOME IN 21 PATIENTS
Authors: COOGAN CL FOSTER RS SIMMONS GR TOGNONI PG ROTH BJ DONOHUE JP
Citation: Cl. Coogan et al., BILATERAL TESTICULAR-TUMORS - MANAGEMENT AND OUTCOME IN 21 PATIENTS, Cancer, 83(3), 1998, pp. 547-552
DECISION-ANALYSIS FOR AVOIDING POSTCHEMOTHERAPY SURGERY IN PATIENTS WITH DISSEMINATED NONSEMINOMATOUS GERM-CELL TUMORS
Authors: DEBONO DJ HEILMAN DK EINHORN LH DONOHUE JP
Citation: Dj. Debono et al., DECISION-ANALYSIS FOR AVOIDING POSTCHEMOTHERAPY SURGERY IN PATIENTS WITH DISSEMINATED NONSEMINOMATOUS GERM-CELL TUMORS, Journal of clinical oncology, 15(4), 1997, pp. 1455-1464
DEVELOPING ISSUES UNDER THE MASSACHUSETTS PHYSICIAN PROFILE ACT
Authors: DONOHUE JP
Citation: Jp. Donohue, DEVELOPING ISSUES UNDER THE MASSACHUSETTS PHYSICIAN PROFILE ACT, American journal of law & medicine, 23(1), 1997, pp. 115-158
POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION IS EFFECTIVE THERAPY IN SELECTED PATIENTS WITH ELEVATED TUMOR-MARKERS AFTER PRIMARY CHEMOTHERAPY ALONE
Authors: COOGAN CL FOSTER RS ROWLAND RG BIHRLE R SMITH ER EINHORN LH ROTH BJ DONOHUE JP
Citation: Cl. Coogan et al., POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION IS EFFECTIVE THERAPY IN SELECTED PATIENTS WITH ELEVATED TUMOR-MARKERS AFTER PRIMARY CHEMOTHERAPY ALONE, Urology, 50(6), 1997, pp. 957-962
RESIDUAL MASSES AFTER CHEMOTHERAPY FOR METASTATIC TESTICULAR CANCER -THE CLINICAL IMPLICATIONS OF THE ASSOCIATION BETWEEN RETROPERITONEAL AND PULMONARY HISTOLOGY
Authors: STEYERBERG EW DONOHUE JP GERL A TONER GC KOOPS HS FOSSA SD KEIZER HJ
Citation: Ew. Steyerberg et al., RESIDUAL MASSES AFTER CHEMOTHERAPY FOR METASTATIC TESTICULAR CANCER -THE CLINICAL IMPLICATIONS OF THE ASSOCIATION BETWEEN RETROPERITONEAL AND PULMONARY HISTOLOGY, The Journal of urology, 158(2), 1997, pp. 474-478
RESIDUAL PULMONARY MASSES AFTER CHEMOTHERAPY FOR METASTATIC NONSEMINOMATOUS GERM-CELL TUMOR - PREDICTION OF HISTOLOGY
Authors: STEYERBERG EW KEIZER HJ MESSEMER JE TONER GC KOOPS HS FOSSA SD GERL A SLEIJFER DT DONOHUE JP HABBEMA KDF
Citation: Ew. Steyerberg et al., RESIDUAL PULMONARY MASSES AFTER CHEMOTHERAPY FOR METASTATIC NONSEMINOMATOUS GERM-CELL TUMOR - PREDICTION OF HISTOLOGY, Cancer, 79(2), 1997, pp. 345-355
COST- AND RISK-BENEFIT CONSIDERATIONS IN THE MANAGEMENT OF CLINICAL STAGE-I NONSEMINOMATOUS TESTICULAR-TUMORS
Authors: BANIEL J ROTH BJ FOSTER RS DONOHUE JP
Citation: J. Baniel et al., COST- AND RISK-BENEFIT CONSIDERATIONS IN THE MANAGEMENT OF CLINICAL STAGE-I NONSEMINOMATOUS TESTICULAR-TUMORS, Annals of surgical oncology, 3(1), 1996, pp. 86-93
BIOLOGY OF METASTASES AND ITS CLINICAL IMPLICATIONS - TESTICULAR GERM-CELL TUMORS
Authors: DONOHUE JP FOSTER RS LITTLE JS LOEHRER PJ EINHORN LE
Citation: Jp. Donohue et al., BIOLOGY OF METASTASES AND ITS CLINICAL IMPLICATIONS - TESTICULAR GERM-CELL TUMORS, World journal of urology, 14(3), 1996, pp. 197-203
NERVE SPARING POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION FOR ADVANCED TESTICULAR CANCER
Authors: COOGAN CL HEJASE MJ WAHLE GR FOSTER RS ROWLAND RG BIHRLE R DONOHUE JP
Citation: Cl. Coogan et al., NERVE SPARING POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION FOR ADVANCED TESTICULAR CANCER, The Journal of urology, 156(5), 1996, pp. 1656-1658
POSTCHEMOTHERAPY RESECTION OF NONSEMINOMATOUS GERM-CELL TESTICULAR-TUMORS METASTATIC TO THE MEDIASTINUM
Authors: HEJASE MJ DONOHUE JP FOSTER RS BIHRLE R COOGAN CL ROWLAND RG WAHLE GR
Citation: Mj. Hejase et al., POSTCHEMOTHERAPY RESECTION OF NONSEMINOMATOUS GERM-CELL TESTICULAR-TUMORS METASTATIC TO THE MEDIASTINUM, The Journal of urology, 156(4), 1996, pp. 1345-1348
THE CLINICAL IMPLICATIONS OF PROCEDURAL DEVIATIONS DURING ORCHIECTOMYFOR NONSEMINOMATOUS TESTIS CANCER - REPLY
Authors: LEIBOVITCH I BANIEL J FOSTER RS DONOHUE JP
Citation: I. Leibovitch et al., THE CLINICAL IMPLICATIONS OF PROCEDURAL DEVIATIONS DURING ORCHIECTOMYFOR NONSEMINOMATOUS TESTIS CANCER - REPLY, The Journal of urology, 156(2), 1996, pp. 484-484
MALIGNANT TESTICULAR NEOPLASMS IN IMMUNOSUPPRESSED PATIENTS
Authors: LEIBOVITCH I BANIEL J ROWLAND RG SMITH ER LUDLOW JK DONOHUE JP
Citation: I. Leibovitch et al., MALIGNANT TESTICULAR NEOPLASMS IN IMMUNOSUPPRESSED PATIENTS, The Journal of urology, 155(6), 1996, pp. 1938-1942
TERATOMA IN THE ORCHIECTOMY SPECIMEN AND VOLUME OF METASTASIS ARE PREDICTORS OF RETROPERITONEAL TERATOMA IN LOW STAGE NONSEMINOMATOUS TESTIS CANCER
Authors: FOSTER RS BANIEL J LEIBOVITCH I CURRAN M BIHRLE R ROWLAND R DONOHUE JP
Citation: Rs. Foster et al., TERATOMA IN THE ORCHIECTOMY SPECIMEN AND VOLUME OF METASTASIS ARE PREDICTORS OF RETROPERITONEAL TERATOMA IN LOW STAGE NONSEMINOMATOUS TESTIS CANCER, The Journal of urology, 155(6), 1996, pp. 1943-1945
DISCORDANCE BETWEEN SITE OF PRIMARY NONSEMINOMATOUS GERM-CELL TUMOR OF THE TESTIS AND RETROPERITONEAL METASTATIC DISEASE SECONDARY TO ANOMALOUS VENOUS DRAINAGE OF THE TESTIS
Authors: NASH PA DONOHUE JP
Citation: Pa. Nash et Jp. Donohue, DISCORDANCE BETWEEN SITE OF PRIMARY NONSEMINOMATOUS GERM-CELL TUMOR OF THE TESTIS AND RETROPERITONEAL METASTATIC DISEASE SECONDARY TO ANOMALOUS VENOUS DRAINAGE OF THE TESTIS, The Journal of urology, 155(4), 1996, pp. 1393-1394
Risultati: 1-25 | 26-50 | 51-75 | 76-91